EUCTR2005-000722-24-IT进行中（未招募）不适用
PHASE II STUDY WITH CETUXIMAB SINGLE AGENT FOLLOWED BY 5-FU, CETUXIMAB AND PELVIC RADIOTHERAPY AS NEO-ADJUVANT TREATMENT FOR OPERABLE, LOCALLY ADVANCED RECTAL CANCER
AZIENDA OSPEDALIERA POLICLINICO DI MODENA0 个研究点开始时间: 2007年8月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
This study will assess the antimyeloma effects of BHQ880 in patients with smoldering multiple myeloma with high risk of progression to active multiple myelomaEUCTR2010-022029-13-DEovartis Pharma Services AG40
招募中
2 期
A Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Essential Tremor - Part BACTRN12622000408785Praxis Precision Medicines12
招募中
2 期
A Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Essential TremorACTRN12619001052123Praxis Precision Medicines12
进行中（未招募）
不适用
A phase II, randomized trial with single agent trastuzumab or lapatinib in women with metastatic breast cancer iperexpressing HER2 - NDwomen with metastatic breast cancer iperexpressing HER2MedDRA version: 9.1Level: LLTClassification code 10065430MedDRA version: 9.1Level: LLTClassification code 10055113EUCTR2008-001916-18-ITAZIENDA OSPEDALIERA ORDINE MAURIZIANO
进行中（未招募）
1 期
A study to assess effects (how safe and effective) of HM61713 (BI 1482694) (new medicine) on specific type of non-small cell lung cancer, which characterized by being positive to certain type of mutation (T790M) , after treatment with a class of drugs known as (EGFR-TKI). The study will also test the drug concentrations’ changes in the patient blood at certain time points.EUCTR2015-001435-21-DEHanmi Pharmaceutical Co., Ltd.150